Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Arvest Bank Trust Division

Arvest Bank Trust Division lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 210,839 shares of the biopharmaceutical company’s stock after selling 5,823 shares during the quarter. Arvest Bank Trust Division’s holdings in Gilead Sciences were worth $13,363,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Cooper Financial Group raised its holdings in shares of Gilead Sciences by 4.3% during the second quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 149 shares during the period. Alpha Cubed Investments LLC raised its holdings in shares of Gilead Sciences by 0.6% in the 2nd quarter. Alpha Cubed Investments LLC now owns 25,592 shares of the biopharmaceutical company’s stock worth $1,729,000 after acquiring an additional 156 shares during the last quarter. Blume Capital Management Inc. raised its holdings in shares of Gilead Sciences by 4.8% in the 2nd quarter. Blume Capital Management Inc. now owns 3,615 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 165 shares during the last quarter. Perigon Wealth Management LLC raised its holdings in shares of Gilead Sciences by 0.3% in the 2nd quarter. Perigon Wealth Management LLC now owns 51,335 shares of the biopharmaceutical company’s stock worth $3,468,000 after acquiring an additional 165 shares during the last quarter. Finally, Capital Advisors Ltd. LLC grew its position in Gilead Sciences by 26.3% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 796 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 166 shares in the last quarter. 79.91% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, July 15th. Jefferies Financial Group set a $95.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, July 15th. Credit Suisse Group reduced their target price on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a research report on Wednesday, July 31st. Oppenheimer reduced their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and an average target price of $79.27.

Gilead Sciences stock traded up $1.42 during trading hours on Friday, reaching $65.38. The stock had a trading volume of 4,953,000 shares, compared to its average volume of 6,639,518. The company has a fifty day simple moving average of $64.15 and a 200-day simple moving average of $65.25. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.06 and a quick ratio of 2.96. The stock has a market cap of $82.81 billion, a PE ratio of 10.63, a PEG ratio of 3.47 and a beta of 1.09. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $72.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 EPS for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.01. The firm had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The business’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the prior year, the business posted $1.84 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post 6.66 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.85%. The ex-dividend date is Thursday, December 12th. Gilead Sciences’s payout ratio is 40.98%.

In other news, EVP Brett A. Pletcher sold 608 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the sale, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,750,191.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 5,677 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $63.31, for a total transaction of $359,410.87. Following the completion of the sale, the executive vice president now owns 21,521 shares in the company, valued at $1,362,494.51. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,288 shares of company stock worth $1,108,682. 0.20% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: How is inflation measured?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.